证券代码：600829 证券简称：人民同泰 公告编号：2026-003 哈药集团人民同泰医药股份有限公司 控股股东减持计划时间届满暨减持股份结果公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 控股股东持股的基本情况:本次减持计划实施前，哈药集团人 民同泰医药股份有限公司（以下简称"公司"）控股股东哈药集团股 份有限公司（以下简称"哈药股份"）持有公司股份 433,894,354 股， 占公司总股本的 74.82%。股份来源为重大资产重组及其他方式取得。 减持计划的实施结果情况:公司于 2025 年 11 月 20 日披露《控 股股东减持股份计划公告》（公告编号：2025-035）。公司控股股东哈 药股份计划于 2025 年 12 月 11 日至 2026 年 3 月 10 日期间，通过集 中竞价交易方式减持公司股份，拟减持股份数量不超过 5,798,800 股， 占公司总股本的比例不超过 1%。公司于近日收到哈药股份出具的《股 份减持计划实施结果告知函》，截至 2026 年 3 月 10 日，哈 ...

哈药集团人民同泰医药股份有限公司 关于公司董事、总经理辞职及聘任总经理的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 哈药集团人民同泰医药股份有限公司（以下简称"公司"）董事 会于近日收到公司董事、总经理顾丛峰先生递交的辞职报告，因个人 身体原因，顾丛峰先生辞去公司董事、总经理及董事会战略决策委员 会委员等职务，辞职报告自送达董事会之日起生效。 一、董事、总经理离任情况 证券代码：600829 证券简称：人民同泰 公告编号：临 2026-002 截至本公告披露日，顾丛峰先生未持有公司股份，不存在未履行 完毕的公开承诺。公司及公司董事会对顾丛峰先生在任职期间为公司 发展做出的贡献表示衷心的感谢！ 二、聘任总经理的情况 根据《公司法》及《公司章程》的相关规定，公司于 2026 年 3 月 6 日召开第十一届董事会第六次会议，审议通过《关于聘任公司总 经理的议案》。经公司董事会提名委员会审核通过，董事会同意聘任 朱卫东先生为公司总经理（简历详见附件），任期自本次董事会审议 通过之日起至第十一届董事会届满之日止 ...

Core Viewpoint - The company is experiencing significant financial challenges, with declining profits and a weak stock performance, influenced by industry policies and market conditions [2][3][8]. Financial Performance - In the first three quarters of 2025, the company's net profit attributable to shareholders was 112 million yuan, a year-on-year decrease of 45.69% [2]. - The net profit for the third quarter alone was 39.3 million yuan, down 44.51% year-on-year [2]. - The gross margin has further declined to 8.02%, with a net margin of only 1.41%, indicating pressure on profit quality [3]. Market Activity - On February 13, the stock closed at 10.69 yuan, down 1.02%, and hit a 60-day low, with a trading volume of 69.91 million yuan and a turnover rate of 1.12% [1]. - There was a net outflow of 3.72 million yuan from main funds, continuing a trend of net outflows over recent days [4]. - The overall pharmaceutical commercial sector saw a net outflow of 184 million yuan, indicating a weak funding environment that exacerbates selling pressure on individual stocks [5]. Valuation and Technical Indicators - The stock price has fallen below the 60-day moving average, with the MACD histogram turning negative at -0.18, and the KDJ indicator showing an oversold signal with the J line at -4.44 [6]. - The lower support level of the Bollinger Band has shifted to 10.37 yuan, and breaching this level could trigger further technical selling pressure [7]. Industry Environment - The pharmaceutical commercial sector declined by 0.89% due to common industry factors such as deepening centralized procurement and extended medical insurance reimbursement cycles [8]. - Investor sentiment has been cautious ahead of the Spring Festival, leading to reduced positions due to concerns over market volatility during the holiday [8]. Financial Risks - The accounts receivable reached 4.079 billion yuan, accounting for 58.19% of total assets, highlighting significant pressure on cash flow [10]. - Despite efforts to expand the DTP pharmacy business, which saw a revenue increase of 22.81%, it is unlikely to offset the decline in wholesale business in the short term [10]. Future Outlook - The recent stock price breakdown is attributed to weak performance, risk aversion in funding, and technical breakdowns [11]. - Short-term focus should be on the effectiveness of the 10.37 yuan support level and whether first-quarter performance can improve [11]. - While industry policies may drive transformation, the market is more concerned with accounts receivable management and the substantive recovery of profitability [11].

Core Viewpoint - The report highlights the financing, investment, logistics, and merger activities of China's chain pharmacy industry, emphasizing the importance of logistics center construction and the trend of expanding business scale and diversification among leading companies [1][8]. Financing Situation - The primary financing methods for listed companies in the chain pharmacy industry include private placements and convertible bonds, mainly aimed at constructing logistics centers, opening new pharmacies, and supplementing working capital [1]. - Key financing events since 2022 include: - Yifeng Pharmacy raised 2.547 billion yuan for logistics and digital platform upgrades [1]. - Yixin Tang raised up to 1.5 billion yuan for new pharmacies and logistics projects [1]. - Daclin raised 3.025 billion yuan for new chain pharmacies [1]. - Shuyupingmin raised up to 800 million yuan for modern logistics projects [1]. - Jianzhijia raised 410 million yuan for logistics center projects [1]. Investment Activities - From 2020 to 2025, major companies like Daclin, Yifeng Pharmacy, and Laobaixing have been actively investing, with Daclin leading with 36 investment events, followed by Yifeng Pharmacy with 14 and Laobaixing with 13 [5][6]. - The investment purposes include expanding business scale and diversifying operations, with companies investing in subsidiaries across different regions to enhance their market presence [8][10]. Merger and Acquisition Trends - Recent mergers and acquisitions in the chain pharmacy industry are primarily aimed at expanding the scale of midstream enterprises, often involving the acquisition of other pharmacy brands to increase store numbers and improve regional business layouts [11]. - Notable merger events include: - Huaren Health's acquisition of three pharmacy chains in Fujian and Zhejiang to expand its market presence [11]. - Yixin Tang's acquisition of multiple pharmacies in Sichuan to enhance competitiveness [11]. - Laobaixing's acquisition of a pharmacy chain in Anhui to strengthen market position [11]. Logistics Center Development - The construction of logistics centers is identified as a major purpose for financing, with companies focusing on enhancing their supply chain efficiency and operational capabilities [1][8].

Core Insights - The report discusses the development prospects and investment strategies of the Chinese chain pharmacy industry, highlighting key players and market dynamics [1][12]. Industry Overview - The chain pharmacy industry supply chain consists of upstream manufacturers, medical device producers, health product manufacturers, and pharmaceutical logistics suppliers; the midstream is represented by chain pharmacies, while downstream customers include both offline and online clients [1][2]. Key Players - Major listed companies in the chain pharmacy sector include Dazhonglin, Yifeng Pharmacy, and Laobaixing, among others [1][2]. Regional Distribution - Upstream suppliers are primarily located in Beijing, Jiangsu, Hubei, and Hunan, while chain pharmacy operations are concentrated in Hunan, Yunnan, Guangdong, and Shanghai [6]. Financial Performance - By the first half of 2025, three listed chain pharmacy companies, including Guoyao Holdings, Dazhonglin, and Yifeng Pharmacy, are projected to exceed 10 billion yuan in operating revenue, with gross margins above 15%, and Yifeng Pharmacy exceeding 40% [8][9]. Investment Trends - Since 2024, chain pharmacy companies have focused on increasing capital in subsidiaries and acquisitions to improve financial structures and expand sales channels [10]. - Notable investment activities include: - Jianzhijia's capital increase of 466 million yuan across five subsidiaries [11] - Yixintang's investment of 32.8 million yuan in land use rights [11] - Tongrentang's acquisition of a 51% stake in Honghui Pharmaceutical for approximately 10.46 million yuan [11].

Market Overview - The pharmaceutical commercial sector experienced a decline of 0.22% on January 29, with Renmin Tongtai leading the drop [1] - The Shanghai Composite Index closed at 4157.98, up 0.16%, while the Shenzhen Component Index closed at 14300.08, down 0.3% [1] Stock Performance - Notable gainers in the pharmaceutical sector included: - Run Da Medical (603108) with a closing price of 16.43, up 2.88% and a trading volume of 455,600 shares, totaling 756 million yuan [1] - Da Shen Lin (603233) closed at 20.25, up 2.27% with a trading volume of 84,100 shares, totaling 170 million yuan [1] - Hua Ren Health (301408) closed at 22.35, up 0.81% with a trading volume of 267,500 shares, totaling 602 million yuan [1] - Major decliners included: - Renmin Tongtai (600829) closed at 11.77, down 4.70% with a trading volume of 301,800 shares, totaling 357 million yuan [2] - Hai Wang Biological (000078) closed at 3.80, down 4.04% with a trading volume of 2,002,500 shares, totaling 771 million yuan [2] - Rui Kang Pharmaceutical (002589) closed at 3.40, down 2.86% with a trading volume of 757,500 shares, totaling 260 million yuan [2] Capital Flow - The pharmaceutical commercial sector saw a net outflow of 310 million yuan from major funds, while retail investors contributed a net inflow of 388 million yuan [2] - The detailed capital flow for selected stocks showed: - Run Da Medical had a net inflow of 61.41 million yuan from major funds, but a net outflow of 44.17 million yuan from retail investors [3] - Kyushu Tong (600998) experienced a net inflow of 20.92 million yuan from major funds, with a net outflow of 7.80 million yuan from retail investors [3] - Other stocks like Da Shen Lin and Lao Bai Xing also showed mixed capital flows with varying degrees of net inflows and outflows [3]

Market Overview - The pharmaceutical commercial sector declined by 1.0% on January 28, with Renmin Tongtai leading the drop [1] - The Shanghai Composite Index closed at 4151.24, up 0.27%, while the Shenzhen Component Index closed at 14342.9, up 0.09% [1] Stock Performance - Notable gainers in the pharmaceutical sector included: - China Medicine (600056) with a closing price of 11.21, up 2.28% and a trading volume of 531,600 shares, totaling 593 million yuan [1] - Yixin Pharmacy (002727) closed at 14.09, up 0.64% with a trading volume of 220,100 shares, totaling 311 million yuan [1] - Major decliners included: - Renmin Tongtai (600829) closed at 12.35, down 4.93% with a trading volume of 432,700 shares, totaling 537 million yuan [2] - Saili Medical (603716) closed at 23.29, down 4.71% with a trading volume of 157,600 shares, totaling 374 million yuan [2] Capital Flow - The pharmaceutical commercial sector experienced a net outflow of 528 million yuan from institutional investors, while retail investors saw a net inflow of 603 million yuan [2] - The capital flow for key stocks showed: - China Medicine had a net inflow of 32.15 million yuan from institutional investors, but a net outflow of 15.57 million yuan from retail investors [3] - Shanghai Pharmaceutical (601607) had a net inflow of 9.01 million yuan from institutional investors, with a significant net outflow of 32.51 million yuan from retail investors [3]

Core Viewpoint - The recent policy document issued by multiple government departments aims to promote high-quality development in the pharmaceutical retail industry, leading to a surge in stock prices of major pharmacy chains in the A-share market [1][3]. Group 1: Policy Measures - The policy document outlines 18 specific measures to enhance the pharmaceutical retail sector, focusing on professionalization, digitalization, and regulatory compliance [1]. - Key initiatives include improving pharmacy service capabilities, supporting mergers and acquisitions among retail pharmacies, and fostering a fair competitive market environment [2]. Group 2: Market Impact - The policy is expected to drive mergers and acquisitions, increasing industry concentration and facilitating the transition of pharmacies from "drug sales" to "comprehensive services" [2]. - Leading pharmacy chains such as Yifeng Pharmacy and Dacelins have seen significant stock price increases, with Yifeng's store count projected to exceed 14,666 by September 2025, and Dacelins operating 17,385 stores [3]. Group 3: Benefits to Other Companies - Other pharmaceutical companies like Shanghai Pharmaceuticals, China Resources Pharmaceutical, and Jiuzhoutong are anticipated to benefit from the integration of wholesale and retail operations, enhancing their revenue potential [3]. - The policy encourages retail pharmacies to enhance their service capabilities, which may benefit digital and supply chain service providers in the healthcare sector [4].

Core Viewpoint - The pet economy sector experienced a slight increase of 0.51% on January 23, with Renmin Tongtai leading the gains [1] Market Performance - The Shanghai Composite Index closed at 4136.16, up by 0.33% - The Shenzhen Component Index closed at 14439.66, up by 0.79% [1] Capital Flow - The pet economy sector saw a net outflow of 514.64 thousand yuan from main funds - Retail investors contributed a net inflow of 5653.9 thousand yuan - Speculative funds experienced a net outflow of 5139.26 thousand yuan [1]

Market Performance - The pharmaceutical commercial sector increased by 3.69% on January 23, with Yifeng Pharmacy leading the gains [1] - The Shanghai Composite Index closed at 4136.16, up 0.33%, while the Shenzhen Component Index closed at 14439.66, up 0.79% [1] Individual Stock Performance - Yifeng Pharmacy (603939) closed at 24.81, up 10.02% with a trading volume of 284,300 shares and a transaction value of 703 million yuan [1] - Dazhenglin (603233) closed at 21.27, up 6.88% with a trading volume of 211,400 shares and a transaction value of 451 million yuan [1] - Renmintongtai (600829) closed at 12.04, up 6.08% with a trading volume of 531,800 shares and a transaction value of 649 million yuan [1] - Laobaixing (603883) closed at 16.44, up 5.93% with a trading volume of 519,000 shares and a transaction value of 843 million yuan [1] - Runda Medical (603108) closed at 17.72, up 5.48% with a trading volume of 451,600 shares and a transaction value of 792 million yuan [1] Capital Flow - The pharmaceutical commercial sector saw a net inflow of 368 million yuan from main funds, while retail funds experienced a net outflow of 294 million yuan [2] - The main funds' net inflow for Renmintongtai was 111 million yuan, accounting for 17.03% of its total trading volume [3] - Yifeng Pharmacy had a main fund net inflow of 110 million yuan, representing 15.70% of its total trading volume [3]